Impact of the AT2 Receptor Agonist C21 on Blood Pressure and Beyond
- First Online:
- Cite this article as:
- Foulquier, S., Steckelings, U.M. & Unger, T. Curr Hypertens Rep (2012) 14: 403. doi:10.1007/s11906-012-0291-6
- 387 Views
It is now widely accepted that the angiotensin AT2 receptor (AT2R) plays an important protective role during pathophysiologic conditions, acting as a repair system. The development of the first selective nonpeptide AT2R agonist C21 accelerated our understanding of AT2R-mediated protective signaling and actions. This article reviews the impact of C21 on blood pressure in normotensive and hypertensive animal models. Although C21 does not act as a classical antihypertensive drug, it could be useful in preventing hypertension-induced vascular and other end organ damages via anti-apoptotic, anti-fibrotic and anti-inflammatory actions. In particular, a strong body of evidence started to emerge around its anti-inflammatory feature. This property should be further investigated for potential clinical indications in cardiovascular diseases and beyond.